Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
budigalimab + mFOLFOX6
- Development stage
- Preclinical
- Lead developer
- AbbVie
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Budigalimab + mFOLFOX6 is a combination regimen consisting of budigalimab, a monoclonal antibody targeting programmed cell death protein 1 (PD-1), and mFOLFOX6, a modified FOLFOX6 chemotherapy protocol comprising oxaliplatin, leucovorin (folinic acid), and 5-fluorouracil. Budigalimab acts as an immune checkpoint inhibitor that enhances anti-tumor immune response by blocking PD-1 signaling, while mFOLFOX6 targets dividing cancer cells through cytotoxic chemotherapy. This combination is primarily investigated for its potential synergistic effects in the treatment of solid tumors, especially gastrointestinal cancers.
02
Targets
DNAPDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)TS (Thymidylate synthase)Microtubule
Beyond the preview
Go deeper on budigalimab + mFOLFOX6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on budigalimab + mFOLFOX6.